-DOCSTART- -X- O
Around -X- _ O
10,000 -X- _ O
people -X- _ O
die -X- _ O
each -X- _ O
year -X- _ O
due -X- _ O
to -X- _ O
severe -X- _ B-Patient
dengue -X- _ I-Patient
disease -X- _ I-Patient
, -X- _ O
and -X- _ O
two-thirds -X- _ O
of -X- _ O
the -X- _ O
world -X- _ O
population -X- _ O
lives -X- _ O
in -X- _ O
a -X- _ O
region -X- _ O
where -X- _ O
dengue -X- _ O
disease -X- _ O
is -X- _ O
endemic. -X- _ O
There -X- _ O
has -X- _ O
been -X- _ O
remarkable -X- _ O
progress -X- _ O
in -X- _ O
dengue -X- _ O
virus -X- _ O
vaccine -X- _ O
development -X- _ O
; -X- _ O
however -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
no -X- _ O
licensed -X- _ O
antivirals -X- _ O
for -X- _ O
dengue -X- _ O
disease -X- _ O
, -X- _ O
and -X- _ O
none -X- _ O
appear -X- _ O
to -X- _ O
be -X- _ O
in -X- _ O
clinical -X- _ O
trials. -X- _ O
We -X- _ O
took -X- _ O
the -X- _ O
approach -X- _ O
of -X- _ O
repositioning -X- _ O
approved -X- _ O
drugs -X- _ O
for -X- _ O
anti-dengue -X- _ O
virus -X- _ O
activity -X- _ O
by -X- _ O
screening -X- _ O
a -X- _ O
library -X- _ O
of -X- _ O
pharmacologically -X- _ O
active -X- _ O
compounds. -X- _ O
We -X- _ O
identified -X- _ O
N-desmethylclozapine -X- _ B-Intervention
, -X- _ I-Intervention
fluoxetine -X- _ I-Intervention
hydrochloride -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
salmeterol -X- _ I-Intervention
xinafoate -X- _ I-Intervention
as -X- _ O
dengue -X- _ B-Outcome
virus -X- _ I-Outcome
inhibitors -X- _ I-Outcome
based -X- _ O
on -X- _ O
reductions -X- _ B-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
numbers -X- _ I-Outcome
of -X- _ I-Outcome
infected -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
titers. -X- _ I-Outcome
Dengue -X- _ B-Outcome
virus -X- _ I-Outcome
RNA -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
diminished -X- _ I-Outcome
in -X- _ I-Outcome
inhibitor-treated -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ O
and -X- _ O
this -X- _ O
effect -X- _ O
was -X- _ O
specific -X- _ O
to -X- _ O
dengue -X- _ O
virus -X- _ O
, -X- _ O
as -X- _ O
other -X- _ O
flaviviruses -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
Japanese -X- _ O
encephalitis -X- _ O
virus -X- _ O
and -X- _ O
West -X- _ O
Nile -X- _ O
virus -X- _ O
, -X- _ O
or -X- _ O
other -X- _ O
RNA -X- _ O
viruses -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
respiratory -X- _ O
syncytial -X- _ O
virus -X- _ O
and -X- _ O
rotavirus -X- _ O
, -X- _ O
were -X- _ O
not -X- _ O
affected -X- _ O
by -X- _ O
these -X- _ O
inhibitors. -X- _ O
All -X- _ O
three -X- _ O
inhibitors -X- _ O
specifically -X- _ O
inhibited -X- _ O
dengue -X- _ O
virus -X- _ O
replication -X- _ O
with -X- _ O
50 -X- _ O
% -X- _ O
inhibitory -X- _ O
concentrations -X- _ O
( -X- _ O
IC -X- _ O
( -X- _ O
50 -X- _ O
) -X- _ O
s -X- _ O
) -X- _ O
in -X- _ O
the -X- _ O
high-nanomolar -X- _ O
range. -X- _ O
Estimation -X- _ O
of -X- _ O
negative-strand -X- _ O
RNA -X- _ O
intermediates -X- _ O
and -X- _ O
time-of-addition -X- _ O
experiments -X- _ O
indicated -X- _ O
that -X- _ O
inhibition -X- _ B-Outcome
was -X- _ I-Outcome
occurring -X- _ I-Outcome
at -X- _ I-Outcome
a -X- _ I-Outcome
postentry -X- _ I-Outcome
stage -X- _ I-Outcome
, -X- _ I-Outcome
most -X- _ I-Outcome
probably -X- _ I-Outcome
at -X- _ I-Outcome
the -X- _ I-Outcome
initiation -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
replication. -X- _ I-Outcome
Finally -X- _ O
, -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
inhibition -X- _ O
is -X- _ O
most -X- _ O
likely -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
modulation -X- _ B-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
endolysosomal -X- _ I-Outcome
pathway -X- _ I-Outcome
and -X- _ I-Outcome
induction -X- _ I-Outcome
of -X- _ I-Outcome
autophagy -X- _ I-Outcome
. -X- _ O

